Clinical trials: Focal Seizures
Newly Diagnosed Epilepsy With Focus on Seizure Frequency at Onset and Long-term Seizure Control
Predictive Value of Seizure Frequency at Onset for Long-Term Seizure Control
Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures, and achieving long-term seizure control remains a major therapeutic goal.
- Trial name
- NCT07343609
- Testing
- observational study (no intervention)
- Volunteers
- 100 people
- Sponsor
- Assiut University
Partial Epilepsy
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
- Trial name
- NCT05067634
- Testing
- Xcopri
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- SK Life Science, Inc.
Epilepsy, Dravet Syndrome
Turmeric as Treatment in Epilepsy
This is a single center open-label pilot clinical trial of patients 1-70 years of age with greater than 6 seizures per month diagnosed with Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, or focal seizures.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis
- Trial name
- NCT03254680
- Testing
- Turmeric
- Where
- United States
- Sponsor
- NYU Langone Health
Partial Epilepsies
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.
- Trial name
- NCT00552305
- Testing
- lacosamide
- Where
- 59 sites in United States, Germany and 6 more
- Volunteers
- 370 people
- Sponsor
- UCB Pharma
Epilepsy
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
- Trial name
- NCT00419094
- Testing
- Keppra XR
- Where
- 45 sites in United States, Mexico and 2 more
- Volunteers
- 228 people
- Sponsor
- UCB Pharma
Epilepsy, Focal
A Study of Brivaracetam in Subjects With Partial Onset Seizures
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy
- Trial name
- NCT00175929
- Testing
- Brivaracetam
- Where
- 56 sites in Belgium, Czechia and 7 more
- Volunteers
- 157 people
- Sponsor
- UCB Pharma
Epilepsy, Brain Diseases
Human Epilepsy Project 2: Resistant Focal Seizures Study
The HEP2 study is designed to better understand the challenges of living with focal seizures that do not respond to medication, by following 205 people with medication-resistant focal epilepsy over two years to measure changes in…
- Conditions
- Epilepsy, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases
- Trial name
- HEP2 (NCT03531008)
- Where
- 10 sites in United States
- Volunteers
- 157 people
- Sponsor
- Epilepsy Foundation of America
Epilepsy, Epilepsies, Partial
An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy
The purpose of this study is to evaluate the safety and preliminary effectiveness of the novel compound RWJ-333369 in patients with partial onset seizures who are currently being treated with 1 or 2 concomitant antiepileptic…
- Trial name
- NCT00210652
- Testing
- RWJ 333369:
- Volunteers
- 47 people
- Sponsor
- SK Life Science, Inc.
Epilepsy, Partial, Motor, Epilepsy, Complex Partial
A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of carisbamate as add-on therapy for the treatment of partial onset seizures in patients with epilepsy.
- Conditions
- Epilepsy, Partial, Motor, Epilepsy, Complex Partial, Epilepsy, Simple Partial, Focal Motor Epilepsy
- Trial name
- NCT00740623
- Testing
- Carisbamate
- Volunteers
- 547 people
- Sponsor
- SK Life Science, Inc.
Epilepsy, Partial Seizures
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either…
- Trial name
- PERIWINKLE (NCT01389596)
- Testing
- Pregabalin add-on therapy
- Where
- 86 sites in United States, Belgium and 16 more
- Volunteers
- 295 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy, Partial, Motor, Epilepsy, Complex Partial
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
The purpose of this study is to obtain long-term safety and tolerability information on carisbamate as add-on therapy for the treatment of partial onset seizures in patients with epilepsy.
- Conditions
- Epilepsy, Partial, Motor, Epilepsy, Complex Partial, Epilepsy, Simple Partial, Focal Motor Epilepsy
- Trial name
- NCT00744731
- Testing
- carisbamate
- Volunteers
- 403 people
- Sponsor
- SK Life Science, Inc.
Focal Epilepsy, Generalized Epilepsy
Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong
Background: Epilepsy is a chronic neurological disease which affects approximately 70,000 patients in Hong Kong and 50 billion people worldwide. Among these patients one-third remained unresponsive to antiepileptic agents.
- Conditions
- Focal Epilepsy, Generalized Epilepsy, Partial Seizures, Simple
- Trial name
- NCT03457961
- Testing
- Perampanel
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Focal Epilepsy
Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring
ProbCluster trial aims at making the proof of concept of antiseizure efficacy of the old antigout PBN in SC, in which Panx1 involvement is relevant on SC pathophysiology and in which efficient therapies are still lacking.
- Trial name
- PROBCLUSTER (NCT07318870)
- Testing
- Probenecid
- Where
- 2 sites in France
- Volunteers
- 600 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Partial Seizures With or Without Secondary Generalization
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization
Male and female patients between 16 and 70 years of age who are diagnosed with epilepsy with partial seizures and are taking up to 3 medications for this medical condition will take part in this research study at approximately 80…
- Trial name
- NCT00220415
- Testing
- SPM 927
- Where
- Germany
- Sponsor
- UCB Pharma
Focal Epilepsy, Tonic-Clonic Seizures
An Open-label Study of XEN1101 in Epilepsy
This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of…
- Trial name
- X-TOLE4 (NCT05718817)
- Testing
- XEN1101
- Where
- 153 sites in United States, Argentina and 23 more
- Volunteers
- 880 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Epilepsy, Partial Seizures
Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
The purpose of this study is to determine whether levetiracetam as adjunctive therapy is effective in the treatment of partial seizures, with or without secondary generalization, associated with refractory focal epilepsy.
- Trial name
- Mozart (NCT01392768)
- Testing
- Levetiracetam
- Volunteers
- 126 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Partial Seizures With or Without Secondary Generalization, Epilepsy
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization…
- Trial name
- NCT03083665
- Testing
- Brivaracetam
- Where
- 94 sites in China, Japan and 5 more
- Volunteers
- 449 people
- Sponsor
- UCB Biopharma SRL
Epilepsy, Epilepsies, Partial
Pediatric Epilepsy Study
This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
- Trial name
- NCT00050934
- Testing
- oxcarbazepine
- Where
- 30 sites in United States, Brazil and 2 more
- Volunteers
- 132 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
Pediatric Epilepsy Study in Subjects 1-24 Months
This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive).
- Trial name
- NCT00044278
- Testing
- lamotrigine
- Where
- 70 sites in United States, Argentina and 13 more
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Partial Seizures
Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
To demonstrate the non-inferiority of Levetiracetam (1000 mg/day) versus Carbamazepine Immediate-Release (400 mg/day) used as monotherapy for at least 6 months in a Chinese population with newly or recently diagnosed Epilepsy who…
- Trial name
- NCT01954121
- Testing
- Levetiracetam, Carbamazepine
- Where
- 28 sites in China
- Volunteers
- 436 people
- Sponsor
- UCB Pharma SA